Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1576 - 1600 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Status	Project Number
Ivabradine	cdr_SR0506_Lancora.pdf SR0506_complete_Lancora-Jun15-17_e.pdf SR0506_ Lancora_CL_Report.pdf SR0506_ Lancora_PE_Report.pdf SR0506_Lancora_PI_Submissions.pdf	Oct 11, 2016	Reimbursement Review	Complete	SR0506-000
Lenvima for Differentiated Thyroid Cancer – Details	pcodr-provfund_lenvatinib-lenvima-dtc.pdf pcodr_lenvatinib_lenvima_dtc_fn_rec.pdf pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf pcodr_lenvatinib_lenvima_dtc_fn_egr.pdf pcodr_lenvatinib_lenvima_dtc_in_rec.pdf pcodr_lenvatinib_lenvima_dtc_pagfdk.pdf pcodr_lenvatinib_lenvima_dtc_fdk_eisailtd.pdf pcodr_lenvatinib_lenvima_dtc_coi_tcc.pdf pcodr_lenvatinib_lenvima_dtc_coi_clinicians.pdf	Oct 5, 2016	Reimbursement Review	Complete	PC0080-000
Liraglutide	cdr_SR0505_Victoza_Resubmission.pdf	Sep 21, 2016	Reimbursement Review	Withdrawn	SR0505-000
Opdivo for Metastatic Renal Cell Carcinoma – Details	pcodr-provfund_nivolumab-opdivo-mrcc.pdf pcodr_nivolumab_opdivo_mrcc_fn_rec.pdf pcodr_nivolumab_opdivo_mrcc_fn_cgr.pdf pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf pcodr_nivolumab_opdivo_mrcc_in_rec.pdf pcodr_nivolumab_opdivo_mrcc_pagfdk.pdf pcodr_nivolumab_opdivo_mrcc_fdk_bms.pdf pcodr_nivolumab_opdivo_mrcc_ptfdk_kcc.pdf pcodr_nivolumab_opdivo_mrcc_coi_kcc.pdf	Sep 19, 2016	Reimbursement Review	Complete	PC0074-000
Sarilumab	cdr_SR0503_TBC.pdf SR0503_Kevzara_CL_Report.pdf SR0503_Kevzara_PE_Report.pdf SR0503_Kevzara_PI_Submissions.pdf SR0503_complete_Kevzara-Apr-20-17.pdf	Sep 13, 2016	Reimbursement Review	Complete	SR0503-000
Propiverine hydrochloride	cdr_SR0504_Mictoryl.pdf SR0504_Mictoryl_CL Report.pdf SR0504_Mictoryl_PE_Report.pdf SR0504_Mictoryl_PI_Submissions.pdf SR0504_complete_Mictoryl_Apr-21-17-e.pdf	Sep 9, 2016	Reimbursement Review	Complete	SR0504-000
Yondelis for Liposarcoma or Leiomyoscarcoma – Details	pcodr_provfund_trabectedin_yondelis_lipo-leio.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_cgr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_in_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_pagfdk.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fdk_janssen.pdf pcodr_trabectedin_yondelis_lile_scarcoma_coi_scfc.pdf	Aug 22, 2016	Reimbursement Review	Complete	PC0071-000
Opdivo for Non-Small Cell Lung Cancer – Details	pcodr_provfund_nivolumab_opdivo_nsclc.pdf nivolumab_opdivo_nsclc_fn_rec.pdf nivolumab_opdivo_nsclc_fn_cgr.pdf nivolumab_opdivo_nsclc_fn_egr.pdf nivolumab_opdivo_nsclc_in_rec.pdf nivolumab_opdivo_nsclc_pagfdk.pdf nivolumab_opdivo_nsclc_fdk_bms.pdf nivolumab_opdivo_nsclc_coi_lcc.pdf	Aug 15, 2016	Reimbursement Review	Complete	PC0069-000
Avastin for Platinum-Resistant Ovarian Cancer – Details	pcodr-provfund_bevacizumab_avastin_proc.pdf pcodr_bevacizumab_avastin_proc_fn_rec.pdf pcodr_bevacizumab_avastin_proc_fn_egr.pdf pcodr_bevacizumab_avastin_proc_fn_cgr.pdf pcodr_bevacizumab_avastin_proc-in_rec.pdf pcodr_bevacizumab_avastin_proc_pagfdk.pdf pcodr_bevacizumab_avastin_proc_fdk_roche.pdf pcodr_bevacizumab_avastin_proc_ptfdk_occ.pdf pcodr_bevacizumab_avastin_proc_coi_occ.pdf	Aug 15, 2016	Reimbursement Review	Complete	PC0066-000
ustekinumab	cdr_SR0501_Stelara.pdf SR0501_complete_Stelara_Mar-23-17.pdf SR0501_Stelara_CL_Report.pdf SR0501_Stelara_PE_Report.pdf SR0501_Stelara_PI_Submissions.pdf	Aug 12, 2016	Reimbursement Review	Complete	SR0501-000
Imbruvica for Mantle Cell Lymphoma (relapsed/refractory)	pcodr-provfund_ibrutinib_imbruvica_mcl.pdf pcodr_ibrutinib_imbruvica_mcl_fn_rec.pdf pcodr_ibrutinib_imbruvica_mcl_fn_cgr.pdf pcodr_ibrutinib_imbruvica_mcl_fn_egr.pdf pcodr_ibrutinib_imbruvica_mcl_in_rec.pdf pcodr_ibrutinib_imbruvica_mcl_pagfdk.pdf pcodr_ibrutinib_imbruvica_mcl_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_mcl_ptfdk_lfc.pdf pcodr_ibrutinib_imbruvica_mcl_ptfdk_llsc-ccsn.pdf pcodr_ibrutinib_imbruvica_mcl_coi_lfc.pdf pcodr_ibrutinib_imbruvica_mcl_coi_llsc-ccsn.pdf	Aug 4, 2016	Reimbursement Review	Complete	PC0073-000
Fluorouracil and Salicylic Acid	cdr_SR0498_Actikerall.pdf SR0498_complete_Actikerall-Mar-24-17.pdf SR0498_Actikerall_CL_Report.pdf SR0498_Actikerall_PE_Report.pdf	Aug 4, 2016	Reimbursement Review	Complete	SR0498-000
glycerol phenylbutyrate	cdr_SR0497_Ravicti.pdf SR0497_complete_Ravicti_Mar-23-17.pdf SR0497_Ravicti_CL_Report.pdf SR0497_Ravicti_PE_Report.pdf SR0497_Ravicti_PI_Submissions.pdf	Aug 2, 2016	Reimbursement Review	Complete	SR0497-000
Propranolol oral solution	cdr_SR0496_Hemangiol.pdf SR0496_complete_Hemangiol-Feb-23_17.pdf SR0496_Hemangiol_CL_Report.pdf SR0496_Hemangiol_PE_Report.pdf SR0496_Hemangiol_PI_Submissions.pdf	Jul 27, 2016	Reimbursement Review	Complete	SR0496-000
Ibrance for Advanced Breast Cancer – Details	pcodr_palbociclib_ibrance_abc_rec.pdf pcodr_palbociclib_ibrance_abc_cgr.pdf pcodr_palbociclib_ibrance_abc_egr.pdf	Jul 25, 2016	Reimbursement Review	Withdrawn	PC0068-000
Cotellic for Metastatic Melanoma – Details	pcodr_provfund_cobimetinib_cotellic_metmela.pdf pcodr_cobimetinib_cotellic_metmela_fn_rec.pdf pcodr_cobimetinib_cotellic_metmela_fn_cgr.pdf pcodr_cobimetinib_cotellic_metmela_fn_egr.pdf pcodr_cobimetinib_cotellic_metmela_in_rec.pdf pcodr_cobimetinib_cotellic_metmela_pagfdk.pdf pcodr_cobimetinib_cotellic_metmela_fdk_roche.pdf pcodr_cobimetinib_cotellic_metmela_ptgrpfdk.pdf pcodr_cobimetinib_cotellic_metmela_coi_mnc.pdf pcodr_cobimetinib_cotellic_metmela_coi_sysf.pdf	Jul 18, 2016	Reimbursement Review	Complete	PC0070-000
Adcetris for Hodgkin Lymphoma (post-ASCT consolidation) – Details		Jul 7, 2016	Reimbursement Review	Withdrawn	PC0086-000
Fentanyl buccal	cdr_SR0494_Fentora.pdf SR0494_Fentora_CL_Report.pdf SR0494_Fentora_PE_Report.pdf SR0494_complete_Fentora_Feb-23-17.pdf	Jun 10, 2016	Reimbursement Review	Complete	SR0494-000
Edoxaban	cdr_SR0500_Lixiana_NVAF.pdf SR0500_complete_Lixiana-NVAF_Mar-23-17.pdf SR0500_Lixiana_NVAF_CL_Report.pdf SR0500_Lixiana_NVAF_PE_Report.pdf	Jun 8, 2016	Reimbursement Review	Complete	SR0500-000
Edoxaban	cdr_SR0499_Lixiana_VTE.pdf SR0499_complete_Lixiana_VTE_May_29_17_e.pdf SR0499_Lixiana_VTE_CL_Report.pdf SR0499_Lixiana_VTE_PE_Report.pdf	Jun 8, 2016	Reimbursement Review	Complete	SR0499-000
Cyramza for Non-Small Cell Lung Cancer - Details		May 20, 2016	Reimbursement Review	Cancelled	PC0078-000
Idarucizumab (Drug Plan Submission)	cdr_SR0492_Praxbind.pdf	May 17, 2016	Reimbursement Review	Withdrawn	SR0492-000
Reslizumab	cdr_SR0495_Cinqair.pdf SR0495_complete_Cinqair-Mar-24-17.pdf SR0495_Cinqair_CL_Report.pdf SR0495_Cinqair_PE_Report.pdf SR0495_Cinqair_PI_Submissions.pdf	May 4, 2016	Reimbursement Review	Complete	SR0495-000
Levofloxacin	cdr_SR0493_Quinsair.pdf SR0493_complete_Quinsair_Nov-23-16.pdf SR0493_Quinsair_CL_Report.pdf SR0493_Quinsair_PE_Report.pdf SR0493_Quinsair_PI_Submissions.pdf	May 2, 2016	Reimbursement Review	Complete	SR0493-000
Budesonide	cdr_SR0491_TBC.pdf SR0491_complete_Cortiment-Mar-24-17.pdf SR0491_Cortiment_CL_Report.pdf SR0491_Cortiment_PE_Report.pdf SR0491 Cortiment_PI_Submissions.pdf	Apr 26, 2016	Reimbursement Review	Complete	SR0491-000